X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN LTD GLENMARK PHARMA/
LUPIN LTD
 
P/E (TTM) x 24.5 28.0 87.6% View Chart
P/BV x 3.8 2.9 131.2% View Chart
Dividend Yield % 0.3 0.6 55.4%  

Financials

 GLENMARK PHARMA   LUPIN LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
LUPIN LTD
Mar-18
GLENMARK PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs9931,465 67.8%   
Low Rs729727 100.3%   
Sales per share (Unadj.) Rs325.5349.6 93.1%  
Earnings per share (Unadj.) Rs39.35.6 707.0%  
Cash flow per share (Unadj.) Rs48.729.6 164.5%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.20.5 50.9%  
Book value per share (Unadj.) Rs159.2300.3 53.0%  
Shares outstanding (eoy) m282.17452.08 62.4%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x2.63.1 84.4%   
Avg P/E ratio x21.9197.2 11.1%  
P/CF ratio (eoy) x17.737.1 47.8%  
Price / Book Value ratio x5.43.6 148.2%  
Dividend payout %5.190.0 5.7%   
Avg Mkt Cap Rs m242,991495,502 49.0%   
No. of employees `00013.017.0 76.1%   
Total wages/salary Rs m16,40828,647 57.3%   
Avg. sales/employee Rs Th7,083.99,273.6 76.4%   
Avg. wages/employee Rs Th1,265.41,681.0 75.3%   
Avg. net profit/employee Rs Th855.1147.4 580.0%   
INCOME DATA
Net Sales Rs m91,857158,042 58.1%  
Other income Rs m3741,504 24.9%   
Total revenues Rs m92,230159,545 57.8%   
Gross profit Rs m20,36731,475 64.7%  
Depreciation Rs m2,64410,859 24.3%   
Interest Rs m2,3732,044 116.1%   
Profit before tax Rs m15,72420,076 78.3%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m-810-14,644 5.5%   
Tax Rs m3,8272,885 132.7%   
Profit after tax Rs m11,0882,513 441.3%  
Gross profit margin %22.219.9 111.3%  
Effective tax rate %24.314.4 169.4%   
Net profit margin %12.11.6 759.2%  
BALANCE SHEET DATA
Current assets Rs m68,746122,095 56.3%   
Current liabilities Rs m27,02750,956 53.0%   
Net working cap to sales %45.445.0 100.9%  
Current ratio x2.52.4 106.2%  
Inventory Days Days8585 100.5%  
Debtors Days Days96120 79.7%  
Net fixed assets Rs m24,132129,876 18.6%   
Share capital Rs m282904 31.2%   
"Free" reserves Rs m44,643134,866 33.1%   
Net worth Rs m44,925135,771 33.1%   
Long term debt Rs m45,36364,245 70.6%   
Total assets Rs m117,639263,054 44.7%  
Interest coverage x7.610.8 70.4%   
Debt to equity ratio x1.00.5 213.4%  
Sales to assets ratio x0.80.6 130.0%   
Return on assets %11.41.7 660.6%  
Return on equity %24.71.9 1,333.6%  
Return on capital %19.13.7 514.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15253,141 105.7%   
Fx outflow Rs m8,08419,335 41.8%   
Net fx Rs m48,06833,807 142.2%   
CASH FLOW
From Operations Rs m6,57417,512 37.5%  
From Investments Rs m-7,124-14,073 50.6%  
From Financial Activity Rs m5,432-14,921 -36.4%  
Net Cashflow Rs m1,992-11,482 -17.4%  

Share Holding

Indian Promoters % 48.3 46.6 103.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 31.9 107.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   56,727 98,259 57.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note; Banking and Healthcare Stocks Witness Buying Interest(Closing)

Indian share markets ended their session on a positive note today. Gains were largely seen in the banking sector and healthcare sector.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 25, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS